|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/13/20 Bruker Corp 8-K:2,7 1/13/20 10:186K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 30K 8: R1 Cover HTML 47K 9: XML IDEA XML File -- Filing Summary XML 11K 5: XML XBRL Instance -- tm203271-1_8k_htm XML 14K 10: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.LAB XBRL Labels -- brkr-20200113_lab XML 96K 4: EX-101.PRE XBRL Presentations -- brkr-20200113_pre XML 64K 2: EX-101.SCH XBRL Schema -- brkr-20200113 XSD 12K 7: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 6: ZIP XBRL Zipped Folder -- 0001104659-20-003385-xbrl Zip 11K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i January 13, 2020
(Exact name of registrant as specified in its charter)
| i Delaware | i 000-30833 | i 04-3110160 | ||
| (State or other jurisdiction of | Commission File No. | (I.R.S. Employer | ||
| Incorporation or organization) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| i Common Stock, $0.01 par value per share | i BRKR | i The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
C:
Item 2.02 Results of Operations and Financial Condition.
On January 13, 2020, during the scheduled presentation at the 38th Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) will state that it expects fiscal year 2019 organic revenue growth to be at or near the high end of the Company’s prior organic growth guidance range.
Because the Company’s financial statements for the fiscal year ended December 31, 2019 have not yet been finalized or audited, the preliminary statement regarding the Company’s expectations regarding its fiscal year 2019 organic revenue growth included in this Item 2.02 is subject to change, and the Company’s actual organic revenue growth for this period may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference.
The information furnished in Item 2.02 and Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Forward Looking Statements
Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management’s expectations regarding our fiscal year 2019 performance, including our organic revenue growth. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the preliminary nature of the Company’s fiscal year 2019 financial information, which is subject to completion of the Company’s year-end-audit, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2018. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BRUKER CORPORATION (Registrant) | ||
| Date: January 13, 2020 | By: | /s/GERALD N. HERMAN |
| Gerald N. Herman | ||
| Chief Financial Officer | ||
C:
C: 2
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 1/13/20 | |||
| 12/31/19 | 10-K, NT 10-K, SD | |||
| 12/31/18 | 10-K, SD | |||
| List all Filings | ||||